Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Mid-range Performer

1711.4000 1.40 (0.08%)

NSE Sep 10, 2025 09:17 AM

55.98% Gain from 52W Low

Volume: 650

Eris Lifesciences Ltd.

18 May 2023

1711.40

0.08%

Eris Lifesciences (BUY): Integration costs weigh on quarter

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

Consolidated Q4 revenue/EBITDA growth of 32%/23% YoY missed consensus by 3%/10%

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings